Provided by Tiger Trade Technology Pte. Ltd.

Viking Therapeutics

33.89
-0.4700-1.37%
Post-market: 33.920.0300+0.09%19:59 EDT
Volume:1.50M
Turnover:51.30M
Market Cap:3.95B
PE:-7.26
High:34.98
Open:34.79
Low:33.47
Close:34.36
52wk High:43.15
52wk Low:22.96
Shares:116.65M
Float Shares:110.00M
Volume Ratio:0.91
T/O Rate:1.37%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.6676
EPS(LYR):-3.1920
ROE:-88.85%
ROA:-51.86%
PB:9.68
PE(LYR):-10.62

Loading ...

Viking Therapeutics Q1 EPS USD -1.37 VS. Ibes Estimate USD -1.01

THOMSON REUTERS
·
Apr 30

Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

THOMSON REUTERS
·
Apr 30

U.S. Earnings Preview: After Market Close April 29

Dow Jones
·
Apr 30

Viking Therapeutics options imply 7.0% move in share price post-earnings

TIPRANKS
·
Apr 30

Viking Therapeutics Inc expected to post a loss of $1.01 a share - Earnings Preview

Reuters
·
Apr 28

Viking Therapeutics to report first-quarter results, host conference call

Reuters
·
Apr 23

Top Calls on Wall Street: Nvidia, Apple, Tesla, Alphabet, Cava, Netflix, Airbnb, Viking and More

Tiger Newspress
·
Apr 22

Health Care Up After UnitedHealth Earnings -- Health Care Roundup

Dow Jones
·
Apr 22

Viking Therapeutics to attend Raymond James Biotech/BioPharma Conference in investor meetings

Reuters
·
Apr 10

Viking Therapeutics call volume above normal and directionally bullish

TIPRANKS
·
Apr 10

Viking Therapeutics May Benefit From New Era for Weight Loss Pills, Oppenheimer Says

MT Newswires Live
·
Apr 08

Analysts Offer Insights on Healthcare Companies: Viking Therapeutics (VKTX) and Terumo (OtherTRUMF)

TIPRANKS
·
Apr 08

A Look At Viking Therapeutics (VKTX) Valuation As VANQUISH 2 Reaches Full Phase 3 Enrollment

Simply Wall St.
·
Apr 08

Viking Therapeutics (VKTX) Is Up 7.0% After Completing Enrollment In Key VANQUISH-2 Obesity Trial

Simply Wall St.
·
Apr 06

Viking Therapeutics announces annual shareholder meeting webcast and proxy materials availability

Reuters
·
Apr 02

The Bull Case For Viking Therapeutics (VKTX) Could Change Following Full VK2735 Phase 3 Enrollment Progress

Simply Wall St.
·
Mar 30

Strong Enrollment and Phase 3 Momentum Underpin Buy Rating on Viking Therapeutics’ Obesity Program

TIPRANKS
·
Mar 26

Viking Therapeutics completes enrollment in Phase 3 VANQUISH-2 trial of VK2735; 78-week study targets about 1,000 adults with obesity and type 2 diabetes

Reuters
·
Mar 26

Viking Therapeutics Announces Completion of Enrollment in Phase 3 Vanquish-2 Trial of Vk2735

THOMSON REUTERS
·
Mar 26

Viking Therapeutics Inc - Company Expects to Report Phase 1 Study Results in Q3 2026

THOMSON REUTERS
·
Mar 26